{"id":"tp-40782","type":"article-newspaper","title":"Innovent's IBI354 Records 95% Response Rate in 20-Patient Breast Cancer Study","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/40782","datePublished":"2026-10-26T04:08:00.000Z","dateModified":"2026-10-26T04:08:00.000Z","language":"en","abstract":"A separate Phase 1 study of IBI3001 found response activity in lung cancer and a 6.9-month median progression-free survival in a listed pancreatic cancer group.","section":"Business","references":[]}